Last reviewed · How we verify
MUC-2-KLH vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
MUC-2-KLH vaccine (MUC-2-KLH vaccine) — Memorial Sloan Kettering Cancer Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MUC-2-KLH vaccine TARGET | MUC-2-KLH vaccine | Memorial Sloan Kettering Cancer Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MUC-2-KLH vaccine CI watch — RSS
- MUC-2-KLH vaccine CI watch — Atom
- MUC-2-KLH vaccine CI watch — JSON
- MUC-2-KLH vaccine alone — RSS
Cite this brief
Drug Landscape (2026). MUC-2-KLH vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/muc-2-klh-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab